A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m 2 .

Postdiagnostic metformin or statin use may reduce the risk for death among people with advanced prostate cancer, suggests an analysis of US Veteran Health Administration data.

Adjuvant treatment with metformin does not improve the outcomes of patients with HR-positive or negative early breast cancer, suggest trial data presented at the 2021 San Antonio Breast Cancer Symposium.

Nondiabetic patients with stage III non-small-cell lung cancer do not benefit from the addition of metformin to chemoradiotherapy, suggest results from two phase 2 trials.

Two-thirds (66.4%) of the 152 patients who developed hyperglycemia received antihyperglycemic treatment, most commonly metformin (89.1%), either alone or in combination.

Research published in JAMA Oncology shows that patients with EGFR -mutated lung adenocarcinoma have prolonged progression free survival when tyrosine kinase inhibitor treatment is supplemented with metformin.

Metformin does not improve progression-free survival for patients without diabetes who require chemoradiotherapy for stage IIIA or IIIB non-small-cell lung cancer, suggests research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.

Researchers recommend the use of the antidiabetic agent metformin for the subset of women with human epidermal growth factor receptor-positive and hormone receptor-positive breast cancer who also have diabetes.

Beckmann and team also observed that men receiving metformin or a sulfonylurea were a significant 7% and 6% more likely, respectively, to undergo PSA testing than those not taking any antidiabetic medication.

. © 2019 Springer Healthcare part of the Springer Nature group JAMA ; 322 : 269–271 See also: Stereotactic ablative body radiotherapy benefits show in early NSCLC Chest radiation increases cardiac risk in NSCLC No survival boost for advanced NSCLC with metformin  

Baselga and team note that the incidence of hyperglycemia increased in a dose-dependent manner but was well managed with dose amendments or with the use of metformin and/or insulin.